Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
Kymentie Ferdinande, PhD Researcher UNIPD at University of Padova, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“We are pleased to share our Letter to the Editor in Journal of Thrombosis and Haemostasis (JTH) commenting on the recent work by Cindy Pereira Portela, Lorenzo Alberio and colleagues on the effect of direct oral anticoagulants in cirrhosis.
In this letter, we present complementary in vitro data on rivaroxaban in cirrhosis, in line with those of Portela et al.. Together, these observations support the need for more individualized anticoagulation strategies in cirrhosis, an area that warrants further investigation.
Many thanks to the authors for their interesting reply!”
Title: “Effect of direct oral anticoagulants in cirrhosis: an in vitro study”: comment
Authors: Kymentie Ferdinande, Jill Vercruyssen, Jochen Decaestecker, Charlotte De Vloo, Inge Van Haute, Helena Degroote, Sarah Raevens, Xavier Verhelst, Anja Geerts, Hans Van Vlierberghe, Katrien M. J. Devreese
Read the Full Article on Journal of Thrombosis and Hemostasis
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026